Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...